Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.955 USD | +6.91% | +35.79% | +18.52% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.51% | 88.39M | |
+25.62% | 661B | |
+26.74% | 566B | |
-6.64% | 352B | |
+19.90% | 332B | |
+3.02% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-5.26% | 145B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HOOKIPA Pharma Operations Chief Christine Baker Resigns